The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 01, 2015

Filed:

Feb. 17, 2012
Applicants:

Andrew Asher Protter, Palo Alto, CA (US);

Sarvajit Chakravarty, Mountain View, CA (US);

Inventors:

Andrew Asher Protter, Palo Alto, CA (US);

Sarvajit Chakravarty, Mountain View, CA (US);

Assignee:

Medivation Technologies, Inc., San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/40 (2006.01); A61K 31/44 (2006.01); A61K 31/55 (2006.01); C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61K 31/439 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); C07D 471/14 (2006.01); C07D 471/18 (2006.01); C07D 487/04 (2006.01); C07D 487/14 (2006.01); C07D 471/08 (2006.01); C07D 487/08 (2006.01); C07D 487/18 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/437 (2013.01); A61K 31/439 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); C07D 471/08 (2013.01); C07D 471/14 (2013.01); C07D 471/18 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 487/14 (2013.01); C07D 487/18 (2013.01);
Abstract

Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor αantagonists. The compounds may also bind to and antagonize adrenergic receptor α—The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.


Find Patent Forward Citations

Loading…